Logo

Amgen Receives the US FDA’s Approval of Wezlana (Biosimilar, ustekinumab) for the Treatment of Multiple Inflammatory Diseases

Share this
Amgen

Amgen Receives the US FDA’s Approval of Wezlana (Biosimilar, ustekinumab) for the Treatment of Multiple Inflammatory Diseases

Shots:

  • The approval was granted based on scientific evidence showing high similarity to Stelara with no clinically meaningful differences in safety and effectiveness and met the criteria to be interchangeable with Stelara   
  • Wezlana has been approved for the adult patients with moderate to severe plaque psoriasis who are candidates for phototherapy or systemic therapy, active psoriatic arthritis, moderately to severely active Crohn's disease and moderately to severely active ulcerative colitis
  • It has also been approved for pediatric patients aged 6 yrs. to treat moderate to severe plaque psoriasis who are candidates for phototherapy or systemic therapy and active psoriatic arthritis

Ref: PRNewswire | Image: Amgen

Related News:- Amgen Presents P-III Data for Lumakras and Vectibix in Metastatic Colorectal Cancer at ESMO 2023

PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com

Click here to­ read the full press release 

Shivani Chandra

Shivani was a content writer at PharmaShots. She has a keen interest in recent innovations in the life sciences industry. She was covering news related to Product approvals, clinical trial results, and updates. We can be contacted at connect@pharmashots.com.

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions